StreetInsider.com News Articles

Form SCHEDULE 13G/A MDxHealth SA Filed by: AWM Investment Company, Inc.

Wed, 08 Jul 2026 15:58:00 -0400

si-local-file:///var/storage/secattach/20260708/26747438.html

Form SCHEDULE 13G/A MDxHealth SA Filed by: AWM Investment Company, Inc.

Wed, 08 Jul 2026 15:58:00 -0400

si-local-file:///var/storage/secattach/20260708/26747438.html

Form 6-K MDxHealth SA For: Jul 02

Thu, 02 Jul 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260702/26727964.html

Form 6-K MDxHealth SA For: Jul 02

Thu, 02 Jul 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260702/26727964.html

Mdxhealth receives Nasdaq minimum bid price deficiency notice

Thu, 02 Jul 2026 16:00:16 -0400

Mdxhealth SA (NASDAQ: MDXH) announced it received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market, dated June 30, 2026, stating the company is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum closing bid price of at least $1.00 per share. A deficiency is triggered when a stock fails to meet this threshold for 30 consecutive business days.

The notification does not affect the company's current listing status. Under Nasdaq Listing Rule 5810(c)(3)(A), the company has 180 calendar

Mdxhealth receives Nasdaq minimum bid price deficiency notice

Thu, 02 Jul 2026 16:00:16 -0400

The notification does not affect the company's current listing status. Under Nasdaq Listing Rule 5810(c)(3)(A), the company has 180 calendar

Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Thu, 02 Jul 2026 16:00:00 -0400

IRVINE, California – July 2, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced that the Company received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated June 30, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure upon

Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Thu, 02 Jul 2026 16:00:00 -0400

Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Thu, 02 Jul 2026 16:00:00 -0400

Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Thu, 02 Jul 2026 16:00:00 -0400

Mdxhealth GPS-ProMPT study published in European Urology Oncology

Mon, 29 Jun 2026 08:01:39 -0400

Mdxhealth SA (NASDAQ: MDXH) announced the peer-reviewed publication of the Oxford GPS-ProMPT study in European Urology Oncology, a journal focused on genitourinary oncology, according to a company press release dated June 29, 2026.

The study, titled "Genomic Prostate Score for identifying biologically low-risk disease in patients with prostate cancer undergoing active surveillance, surgery, or radiotherapy," evaluated 409 men with localized or locally advanced prostate cancer over more than six years. Patients were managed with active surveillance, radical prostatectomy, or radiotherapy.

Lead author Dr. Nikita Sushentsev of Cambridge University Hospitals NHS Foundation Trust said patients with favorable GPS mdx scores showed 92% freedom-from-failure

Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial

Mon, 29 Jun 2026 08:00:00 -0400